Pharmaceutical executives who have led successful FDA or EMA submissions sometimes make a predictable assumption when evaluating MENA market entry: that their existing regulatory expertise transfers directly to new markets.

Europe holds 30% of the global pharma market and is a primary source of in-licensing opportunities for MENA companies. Discover why EMA approval status changes the regulatory equation for MENA submissions. | Nexus Pharmalink